NCT03486236View on ClinicalTrials.gov

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 20, 2016

Primary Completion Date

September 14, 2016

Study Completion Date

September 14, 2016

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-440

VX-440 was administered in TC with TEZ and IVA.

DRUG

TEZ

TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)

DRUG

IVA

IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet

DRUG

Matched Placebos

Placebos matched to VX-440, TEZ, and IVA.

Trial Locations (1)

Unknown

The Medicines Evaluation Unit, Manchester

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT03486236 - A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter